Abstract
Bioassays that predict clinical outcome are essential to optimize cellular anticancer immunotherapy. We have recently developed a robust and simple skin test to evaluate the capacity of tumor-specific T cells to migrate, recognize their targets and exert effector functions. This bioassay detects T cells with an elevated antineoplastic potential and hence rapidly identifies patients responding to immunotherapy
Original language | English |
---|---|
Pages (from-to) | e27219 |
Journal | Oncoimmunology |
Volume | 3 |
Issue number | 1 |
DOIs | |
Publication status | Published - 2014 |